Cicatricial junctional epidermolysis bullosa.
Jonkman MF, de Jong MC, van der Meer JB.
J Am Acad Dermatol. 1994 Aug;31(2 Pt 1):286-8. doi: 10.1016/s0190-9622(08)81983-4.
Cicatricial junctional epidermolysis bullosa.
Haber RM, Hanna W, Ramsay CA, Boxall LB.
J Am Acad Dermatol. 1985 May;12(5 Pt 1):836-44. doi: 10.1016/s0190-9622(85)70105-3.
Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa.
Dellambra E, Pellegrini G, Guerra L, Ferrari G, Zambruno G, Mavilio F, De Luca M.
Hum Gene Ther. 2000 Nov 1;11(16):2283-7. doi: 10.1089/104303400750035825.
Generalized atrophic benign epidermolysis bullosa.
Darling TN, Bauer JW, Hintner H, Yancey KB.
Adv Dermatol. 1997;13:87-119; discussion 120.
Epidermolysis bullosa: variability of expression of cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens in clinically uninvolved skin.
Fine JD.
J Invest Dermatol. 1985 Jul;85(1):47-9. doi: 10.1111/1523-1747.ep12275025.
[Epidermolysis bullosa acquisita: diagnosis by optic immunofluorescent demonstration of junctional antigens and vitamin E treatment].
Hintner H, Schuler G, Fritsch P.
Hautarzt. 1982 Jun;33(6):310-4.
Laminins and human disease.
McGowan KA, Marinkovich MP.
Microsc Res Tech. 2000 Nov 1;51(3):262-79. doi: 10.1002/1097-0029(20001101)51:3<262::AID-JEMT6>3.0.CO;2-V.
The molecular genetics of basement membrane diseases.
Marinkovich MP.
Arch Dermatol. 1993 Dec;129(12):1557-65.
Laminin-332-integrin interaction: a target for cancer therapy?
Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M, Jones JC.
Curr Med Chem. 2008;15(20):1968-75. doi: 10.2174/092986708785132834.
Human skin basement membrane in health and in autoimmune diseases.
Chan LS.
Front Biosci. 1997 Jul 15;2:d343-52. doi: 10.2741/a196.
